Welsh charity reports surge in young people seeking ketamine rehab

Referrals rise from two in 2021 to 112 this year, with users in their 20s describing severe bladder damage

By LineZotpaper
Published
Read Time3 min
A Welsh drugs charity has reported a sharp rise in young people seeking residential treatment for ketamine dependence, with referrals to its detox and rehabilitation facility rising from two in 2021 to 112 so far this year, as users describe being left with severe bladder damage.

Megan Harmes, 24, from Flint in north Wales, first tried ketamine at 14. She told BBC News that bladder problems caused by the drug have left her needing incontinence pads, and that four weeks in rehab is already helping her feel physically better, although it remains unclear whether the damage can be reversed.

Megan, a former aeronautical engineering apprentice, said her use escalated during lockdown, when she was working from home on full pay and the price of ketamine had plummeted. At its worst she was on the drug "all day, every day." She said it helped suppress symptoms she associates with ADHD and borderline personality disorder, but it cost her an apprenticeship and later years of night-shift work entrenched the habit. "For a 22-year-old wearing pads or nappies, it takes away all dignity," she said. "Back then I really didn't care whether I lived or died. Now I don't want to die."

Jo Moore, who runs the Birchwood rehabilitation facility for the charity Kaleidoscope, said five years ago the centre had a single referral for inpatient ketamine detox. "Since January this year we've seen 112 people come through the door," she said, with half of current clients being supported for ketamine use. Most are aged 18 to 24. "It's very, very cheap and very accessible. That's what allows people to use it more frequently and at large amounts at the same time."

Ketamine, an anaesthetic used in healthcare and veterinary settings, was reclassified as a Class B drug in the UK in 2014. Illicit use among 16 to 59 year olds in the UK was estimated at about 264,000 people in 2024-25, and the number seeking treatment for ketamine use disorders increased twelvefold over a decade.

Mark, who asked to remain anonymous, started using drugs at 18 and by 21 was using "copious amounts" of cocaine and ketamine. At 25, he said, "I probably had the body of an 80-year-old." He regularly passed clots and experienced pain during urination, and the collapse of his nose from snorting drugs destroyed his self-confidence and drew looks of disgust from his own family. He was too ashamed to tell his GP about the ketamine.

Dr Darren Quelch, of the University of South Wales, is researching this group alongside Kaleidoscope. He found some users started as young as 13, and that chronic use causes harm more rapidly than alcohol or Class A drugs, ranging from memory problems and chronic pain to bladder damage and kidney failure. He said young people often struggled in A&E and GP surgeries, where symptoms were not always linked to ketamine use. "There's very little provision for young people experiencing drug and alcohol-related harms, and that has almost left us starting right from the beginning," he said.

Moore said education in schools, colleges and universities appeared to be reducing new presentations of ketamine use, though those who have used for years will continue to need support. Quelch said the scale of the problem and the recoverability of users' bodies remained unclear, and that relapse appeared to be a big problem, with harm returning faster after a period of abstinence.

§

Analysis

Why This Matters

  • One Welsh service has gone from two ketamine referrals in 2021 to 112 so far this year, a trajectory that suggests a drug trend outpacing the treatment system.
  • Physical harms can be severe and fast: bladder damage requiring incontinence pads, chronic pain and kidney failure, with some users needing pads by their early 20s.
  • Clinicians say they do not yet know what treatment works for this group, and services designed for older adults are adapting without an evidence base.

Background

Ketamine is a dissociative anaesthetic used in hospitals and veterinary medicine, and was made a Class B drug in the UK in 2014. Its non-medical use has long been linked by doctors to urinary tract and bladder damage, sometimes called "ketamine bladder," alongside memory problems and chronic pain. The current wave is notable for how young the users are: most of Kaleidoscope's clients are 18 to 24, and habits were often formed while users were still at school.

Key Perspectives

Service providers (Kaleidoscope): Staff see a cheap, highly accessible drug driving young people into addiction at speed. They argue community early intervention is improving and that education is cutting new presentations, but that services must adapt to clients who often arrive with complex medical needs.

Researchers (University of South Wales): Dr Quelch says young ketamine users are inherently different from other treatment populations, that "we actually don't know what the right answer is yet," and that GPs and emergency departments frequently miss the link between symptoms and ketamine use.

Concerns and open questions: The full scale of the problem is unclear, as is how far damaged bladders and other organs can recover. Relapse appears common, and Quelch warns that harm returns faster after resumed use. The NHS and the third sector are adapting as research catches up.

What to Watch

  • The findings of the University of South Wales research into what support works for young ketamine users.
  • Whether Kaleidoscope's referral numbers keep climbing, including a recent rise in adults aged 25 to 34 in Cardiff and south-east Wales.
  • Whether GP and A&E identification of ketamine-related symptoms improves, enabling earlier intervention before severe bladder damage sets in.

Sources

Zotpaper

Written by Rex Doyle on the Science desk. Read for legal risk by Marcus Hale, legal. Edited by Angus Burke, chief sub. Plate by Ollie Flash, picture desk.

1 sourcefirst published
Meet the newsroomHow we workSubscribe